There are 165 ASX-listed companies in the Health Care sector.
Medical Developments International lifted FY26 revenue 9% to $42.6 million as Penthrox demand grew across all regions. Free cash flow improved to $4.2 million.
20 Aug 2026, 09:56 am · 2 min read
Recce Pharmaceuticals will add a 208-patient, active-controlled study to its Australian Phase 3 R327G program. An interim analysis is planned after 104 participants.
19 Aug 2026, 10:52 am · 2 min read
EBOS Group lifted FY26 underlying EBITDA by 5% and completed its $360 million distribution upgrade. FY27 capital spending is expected to fall to about $100 million.
19 Aug 2026, 10:02 am · 2 min read
CSL’s FY26 statutory result swung to a US$2.58 billion loss after impairments and restructuring costs. The group expects about 5% underlying profit growth in FY27.
18 Aug 2026, 10:56 am · 2 min read
Cochlear forecasts a return to underlying profit growth in FY27 after margin pressure and higher investment reduced FY26 earnings. Free cash flow more than doubled despite the profit decline.
18 Aug 2026, 10:08 am · 2 min read
Australian Clinical Labs lifted underlying profit and margins despite lower FY26 revenue. Its FY27 guidance targets revenue of $745 million to $765 million.
17 Aug 2026, 10:57 am · 3 min read
ResMed lifted fiscal 2026 revenue by 10% and expanded its gross margin to 61.1%. Sleep-health demand drove growth as the company acquired Noctrix and agreed to sell MatrixCare.
14 Aug 2026, 12:04 pm · 2 min read
All five EW-001 patients still under follow-up in March remained alive and on study in July. Higher-dose data support AdAlta’s planned Australian Phase 1 trial.
10 Aug 2026, 11:05 am · 2 min read
CleanSpace received its largest industrial enterprise order, worth about A$1.9 million, for fulfilment in the first quarter of FY27. It follows a completed A$600,000 order from the same Indonesian mining account.
10 Aug 2026, 10:35 am · 2 min read
AVITA Medical raised its 2026 revenue outlook to $86 million-$89 million after record quarterly sales. The company expects fourth-quarter cash flow breakeven.
07 Aug 2026, 10:54 am · 2 min read
30-day announcements
| Rank | ASX code | Company | 30-day announcements |
|---|---|---|---|
| 1 | RAD | RADIOPHARM THERANOSTICS LIMITED | 19 |
| 2 | CBL | CONTROL BIONICS LIMITED | 16 |
| 3 | COH | COCHLEAR LIMITED | 16 |
| 4 | EBO | EBOS GROUP LIMITED | 16 |
| 5 | ENL | ENLITIC INC. | 16 |
Bold Investors provides factual news coverage of ASX company announcements. Nothing on this page is financial advice. Articles are grounded in the company's own announcements.
